Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. (BLCM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
blcm · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bellicum Pharmaceuticals, Inc. (BLCM) measures how much investors pay for each dollar of the company's trailing earnings. BLCM's current PE ratio of N/A is calculated by dividing its stock price of $0.07 by its TTM earnings per share of -$0.81.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2012 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bellicum Pharmaceuticals, Inc.You BLCM | $1M | N/A | — | -$0.81 |
 Acorda Therapeutics, Inc. ACOR | $1M | N/A | — | -$203.59 |
 BIOLASE, Inc. BIOL | $1M | N/A | — | -$16.14 |
 Impel Pharmaceuticals Inc. IMPL | $1M | N/A | — | -$5.52 |
 Infinity Pharmaceuticals, Inc. INFIQ | $0M | N/A | — | -$0.50 |
 9 Meters Biopharma, Inc. NMTRQ | $0M | N/A | — | — |
 InVivo Therapeutics Holdings Corporation NVIV | $1M | N/A | — | -$6.62 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.81 | — | |
2021-12-31 FY2021 | — | $-0.83 | — | |
2020-12-31 FY2020 | — | $-1.50 | — | |
2019-12-31 FY2019 | — | $-26.92 | — | |
2018-12-31 FY2018 | — | $-24.37 | — | |
2017-12-31 FY2017 | — | $-28.94 | — | |
2016-12-31 FY2016 | — | $-25.69 | — | |
2015-12-31 FY2015 | — | $-18.43 | — | |
2014-12-31 FY2014 | — | $-33.47 | — | |
2013-12-31 FY2013 | — | $-8.11 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bellicum Pharmaceuticals, Inc. (BLCM) measures how much investors pay for each dollar of the company's trailing earnings. BLCM's current PE ratio of N/A is calculated by dividing its stock price of $0.07 by its TTM earnings per share of -$0.81.
Frequently asked questions
BLCM pe ratio · 6 questionsBLCM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.07 and TTM EPS of -$0.81. Data sourced from Financial Modeling Prep via BLCM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bellicum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09